Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
13 p, 1.0 MB Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia : A comparative study of the ALWP EBMT / Sanz, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ; Galimard, J. E. (EBMT Paris Office. Hospital Saint Antoine) ; Labopin, Myriam (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ; Afanasyev, B. (First State Pavlov Medical University of St. Petersburg. Raisa Gorbacheva Mem. Research Institute for Paediatric Oncology. Hematology. and Transplantation) ; Angelucci, Emanuele (Department of Haematology. IRCCS Ospedale Policlinico San Martino) ; Ciceri, Fabio (Haematology and BMT) ; Blaise, Didier (Programme de Transplantation and Therapie Cellulaire. Centre de Recherche en Cancérologie de Marseille. Institut Paoli Calmettes) ; Cornelissen, J. J. (Department of Hematology. Erasmus MC Cancer Institute. University Medical Center Rotterdam) ; Meijer, E. (Department of Hematology (Br 250). VU University Medical Center) ; Diez-Martin, J. L. (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; Koc, Y. (Stem Cell Transplant Unit. Medical Park Hospitals) ; Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Castagna, L. (Transplantation Unit. Department of Oncology and Haematology. Istituto Clinico Humanitas) ; Savani, B. N. (Vanderbilt University Medical Center) ; Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ; Nagler, Arnon (ALWP of the EBMT Office. Saint Antoine Hospital) ; Mohty, Mohamad (Department of Hematology. Hopital Saint Antoine. Sorbonne University) ; Universitat Autònoma de Barcelona
Background: The use of post-transplant cyclophosphamide (PTCy) is highly effective in preventing graft-versus-host disease (GVHD) in the haploidentical (Haplo) transplant setting and is being increasingly used in matched sibling (MSD) and matched unrelated (MUD) transplants. [...]
2020 - 10.1186/s13045-020-00882-6
Journal of hematology & oncology, Vol. 13 Núm. 1 (june 2020) , p. 46  
2.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.